GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Float Percentage Of Total Shares Outstanding

Moderna (LTS:0A45) Float Percentage Of Total Shares Outstanding : 75.93% (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Moderna Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Moderna's float shares is 290.99 Mil. Moderna's total shares outstanding is 383.24 Mil. Moderna's float percentage of total shares outstanding is 75.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Moderna's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Moderna's Institutional Ownership is 48.82%.

Moderna Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Moderna's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=290.99/383.24
=75.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna (LTS:0A45) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
BNTX BGNE ALNY SGEN BMRN RPRX LEGN INCY UTHR SRPT OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB XKRX:068270
Traded in Other Exchanges
MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria
Address
200 Technology Square, Cambridge, MA, USA, 02139
Website
https://www.modernatx.com
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines